Lead Candidate VP-001 for Treatment of Retinitis Pigmentosa Type 11 Moves Closer to Clinical Development; Larger Animal Model Readouts on Track for 2021, with IND Submission Expected in mid 2022
First Preclinical Study in the CNS Shows Company's PPMO Technology Can Be Successfully Applied Across High Value Target Tissues Beyond The Eye; Company Expects to Nominate CNS Candidate This Year
Three U.S.-Based, Biopharma Industry Leaders Join Company to Drive Clinical Translation of Pipeline Programs, Including a Chief Development Officer and Board Directors; More Executive Appointments Expected in the Coming Months
PR Newswire
NEW YORK and PERTH, Australia, April 30, 2021
